Biopharma development & formulation intelligence
We develop AI-powered products that help biopharma teams and CDMOs make better development decisions, see risk before it becomes delay, and connect critical scientific, operational and regulatory information.
The problem
Critical scientific, analytical, quality, partner, regulatory and operational information still lives in separate teams and separate systems. Gaps surface late. Risks surface later. Programs lose time to information that already existed somewhere in the organisation.
We build the products that connect it.
BioXion
An AI-powered development intelligence platform for biopharmaceutical companies and CDMOs. It connects program development, partner programs, analytical, quality, regulatory and supply chain data — and gives leadership the visibility to act before programs fall behind.
01
Program development data lives in one system, CDMO performance in another, quality events in a third. BioXion aggregates the signals across every development function into one program view.
02
By the time a signal reaches leadership it is usually already a problem. BioXion surfaces cross-functional risk while the window to act is still open.
03
FDA, EMA and ICH guidance tracked manually has no link to active programs. BioXion monitors guidance continuously and scores submission gaps per program.
04
They tell you what happened. BioXion is built to indicate what is about to go wrong — and what it is likely to cost the program in time.
05
BioXion is deliberately non-GxP. It structures and links program information without touching your QMS, LIMS or ELN — a decision-support layer, not the system of record for regulated GMP data.
FormulytiX
FormulytiX exists to close that gap — combining scientific data, interpretable modelling and regulatory knowledge so a formulation position can be argued while the decision is still inexpensive to change.
Illustrative representation; change burden varies by modality, dosage form and development programme.
01
Early on you can still change almost anything about a formulation, and changing it costs little. Both of those facts reverse as development proceeds — steadily, and in opposite directions.
02
Viscosity at target concentration, aggregation behaviour, degradation pathways, excipient and device compatibility — these become visible in the laboratory months into development. By then the inexpensive window has closed.
03
It brings scientific data, precedent from comparable molecules, predictive modelling and regulatory expectations together early — so the formulation position is informed while the decision is still reversible.
04
Every output carries the reasoning that produced it — what it is based on, how confident it is, and which regulatory expectations it maps to. The laboratory still decides. FormulytiX decides where to look first.
NeXus
NeXus is the developing AI and intelligence layer designed to support advanced reasoning, contextual analysis and explainable recommendations across the Helvetia Tech Solutions product ecosystem.
Scientific, operational and regulatory context connected in one chain of inference rather than isolated model outputs.
The same data means different things at different stages of development. NeXus keeps that context attached.
No output that a reviewer, partner or regulator could not follow back to its evidence.
Approach
We do not start with generic software features. We start with the scientific, operational and regulatory decisions biopharma teams need to make, the information they rely on, and the gaps that slow development.
Our products are shaped around real industry workflows and developed in collaboration with research, technology and industry partners.
Beyond our own platforms, Helvetia Tech Solutions supports the development of IVF Companion, a digital healthcare platform created by Aleksandra Svonja.
Critical scientific, analytical, quality, partner, regulatory and operational information is still fragmented across teams and systems. I founded Helvetia Tech Solutions to build products that connect biopharma development intelligence through BioXion and advance formulation and excipient decisions through FormulytiX.
Partnerships
We are open to discussions with organisations interested in product pilots, design partnerships, scientific validation, technology collaboration or strategic investment.